YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com-- Citi reiterated its top picks in the medtech sector, highlighting Abbott Laboratories and Dexcom as standout opportunities while pointing to diverging fortunes across the industry. Before you buy NVIDIA: our AI model's stoc…
Glaukos GKOS shares have surged 67.9% year to date, significantly outperforming its industry's 8.4% decline. The S&P 500 Index has returned 12% during the period. The rally reflects a sharp acceleration in operating momentum, supported by…
Image source: The Motley Fool. DATE Wed, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Trip Taylor Co-Founder and Chief Executive Officer - Paul Badawi Chief Financial Officer - Jim Rodberg Chief Operating Officer - A…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. The fair value estimate for Sight Sciences has shifted from US$9.35 to US$8.40, pointing to a more measured central valuation in th…
MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform eye care and im…
Integer (ITGR) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.55 per share a year ago. These figures are adjusted for non-recurring items. This q…
Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring…
MENLO PARK, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies inte…
Over the last 7 days, the U.S. market has dropped by 2.7%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. For investors interested in smaller or newer companies, penny stocks — despite being a…
Earnings Call Insights: Sight Sciences (SGHT) Q1 2026 MANAGEMENT VIEW * "We delivered a strong start to 2026 with first quarter results that demonstrated a return to double-digit revenue growth, continued strength in gross margin and disci…
Sight Sciences, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Achieved a return to double-digit total revenue growth driven by the third consecutive quarter of Interventional Glaucoma expansion and a n…
MENLO PARK, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care,…
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to t…
MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies…
Over the last 7 days, the market has dropped 1.9%, although it is up 15% over the past year, with earnings forecast to grow by 15% annually. While penny stocks might seem like a nod to bygone trading days, they still offer relevant opportu…
Sight Sciences, Inc. Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOBE…
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight Sciences executive officers and whether…
(RTTNews) - Sight Sciences, Inc. (SGHT), an eyecare technology company, reported financial results for the fourth quarter and full year 2025. In addition, it provided guidance for the full year 2026. For the fourth quarter, net loss narrow…
Sight Sciences logo Key Points Company reframed around an “interventional” strategy and scored a reimbursement milestone for CPT 0563T, fueling early TearCare traction (Q4 interventional dry eye revenue $0.7M from ~700 SmartLids across ~80…
Earnings Call Insights: Sight Sciences (SGHT) Q4 2025 MANAGEMENT VIEW * CEO Paul Badawi stated that the company “ended 2025 with solid execution across our business, highlighted by fourth quarter revenue growth in both segments, strong gro…
Image source: The Motley Fool. DATE Wednesday, March 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Paul Badawi Chief Financial Officer — Jim Rodberg Chief Operating Officer — Alison Bauerlein Need a quote from a Motle…
Image source: The Motley Fool. DATE Wednesday, March 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Paul BadawiChief Financial Officer — Jim RodbergChief Operating Officer — Alison Bauerlein Need a quote from a Motley…
* Sight Sciences press release [https://seekingalpha.com/pr/20424655-sight-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-initiates-full] (SGHT [https://seekingalpha.com/symbol/SGHT]): Q4 GAAP EPS of -$0.08 beats…
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies…
[silhouette form of bull on technical financial graph 3d illustration] monsitj As 2026 opens with investors seeking dependable small-cap exposure in an uncertain but gradually improving macro environment, below is a list of the top 10 smal…
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies inte…
Inogen, Inc. INGN is well-poised for growth in the coming quarters due to high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid third-quarter 2025 performance and a strong product portfolio, seems justi…
[Digital Intelligence - AI Icon Illuminated Against Financial Data and Binary Streams] J Studios Wall Street research looks to be shifting from endorsing the classic AI trade to AI adopters. Instead of the chipmakers and hyperscalers in th…
The Cooper Companies, Inc. COO delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.15, which improved 11% year over year. The figure beat the Zacks Consensus Estimate of $1.11 by 3.6%. Operational improvements drov…
Inogen, Inc. INGN is well-poised for growth in the coming quarters due to high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid third-quarter 2025 performance and a strong product portfolio, seems justi…
Earnings Call Insights: Sight Sciences (SGHT) Q3 2025 MANAGEMENT VIEW * Paul Badawi, Co-Founder, President, CEO & Director, reported, "Our strong third quarter results were driven by excellent performance by our Surgical Glaucoma team, whe…
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items…
Image source: The Motley Fool. DATE Thursday, November 6, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder and Chief Executive Officer — Paul Badawi Chief Financial Officer — Jim Rodberg Chief Operating Officer — Ali Bauerlein Need a quot…
Steris (STE) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.14 per share a year ago. These figures are adjusted for non-recurring items. This qu…
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies inte…
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies inte…